Absolute lymphocyte count and risk of short-term infection in patients with immune thrombocytopenia

Annals of Hematology

Volumn 93, Issue 6, 2014, Pages 1023-1029

  Hu, Ming Hung ^a,b,d   Yu, Yuan Bin ^a,b   Huang, Yu Chung ^a,b,c   Gau, Jyh Pyng ^a,b   Hsiao, Liang Tsai ^a,b   Liu, Jin Hwang ^a,b   Chen, Ming Huang ^a,b   Chiou, Tzeon Jye ^a,b   Chen, Po Min ^a,b   Tzeng, Cheng Hwai ^a,b   Liu, Chun Yu ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c Taoyuan Veterans Hospital   (Taiwan)

^d CARDINAL TIEN HOSPITAL   (Taiwan)

Author keywords

Absolute lymphocyte count (ALC); Immune thrombocytopenia (ITP); Infection; Lymphopenia

Indexed keywords

METHYLPREDNISOLONE; STEROID;

ADULT; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BLEEDING; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; INFECTION RISK; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; STEROID THERAPY; SURVIVAL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFECTION; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; SPLENECTOMY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902290275     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2014-3     Document Type: Article

References (41)

1. Portielje JE, Westendorp RG, Kluin-Nelemans HC et al (2001) Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 97:2549-2554
2. Mazzucconi MG, Fazi P, Bernasconi S et al (2007) Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 109:1401-1407 (Pubitemid 46239570)
3. Norgaard M, Jensen AO, Engebjerg MC et al (2011) Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Blood 117:3514-3520
4. Daou S, Federici L, Zimmer J et al (2008) Idiopathic thrombocytopenic purpura in elderly patients: a study of 47 cases from a single reference center. Eur J Intern Med 19:447-451
5. Huang YC, Liu CJ, Liu CY et al (2011) Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. Ann Hematol 90:1145-1151
6. Siddiqui M, Ristow K, Markovic SN et al (2006) Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 134:596-601 (Pubitemid 44253601)
7. Cox MC, Nofroni I, Ruco L et al (2008) Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma 49:1745-1751
8. George JN, Woolf SH, Raskob GE et al (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88:3-40 (Pubitemid 26230668)
9. Neunert C, Lim W, Crowther M et al (2011) The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117:4190-4207
10. Godeau B, Chevret S, Varet B et al (2002) Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet 359:23-29 (Pubitemid 34119192)
11. Cheng Y, Wong RS, Soo YO et al (2003) Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 349:831-836 (Pubitemid 37025402)
12. Figueroa M, Gehlsen J, Hammond D et al (1993) Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med 328:1226-1229 (Pubitemid 23115701)
13. Boruchov DM, Gururangan S, Driscoll MC et al (2007) Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood 110:3526-3531 (Pubitemid 350159616)
14. Ghanima W, Godeau B, Cines DB et al (2012) How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 120:960-969
15. Huang JJ, Jiang WQ, Lin TY et al (2011) Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol 22:149-155
16. Hung MH, Yu YB, Hsiao LT et al (2013) Absolute lymphocyte count predicts response to rituximab-containing salvage treatment for relapsed/refractory B-cell non-Hodgkin's lymphoma with prior rituximab exposure. J Chin Med Assoc 76:195-200
17. Oki Y, Yamamoto K, Kato H et al (2008) Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. Eur J Haematol 81:448-453
18. Rodeghiero F, Stasi R, Gernsheimer T et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113:2386-2393
19. Panitsas FP, Theodoropoulou M, Kouraklis A et al (2004) Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 103:2645-2647 (Pubitemid 38393019)
20. Wang T, Zhao H, Ren H et al (2005) Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica 90:914-923 (Pubitemid 41020294)
21. Semple JW, Provan D (2012) The immunopathogenesis of immune thrombocytopenia: T cells still take center-stage. Curr Opin Hematol 19:357-362
22. Semple JW (1998) Immunobiology of T helper cells and antigen-presenting cells in autoimmune thrombocytopenic purpura (ITP). Acta Paediatr Suppl 424:41-45
23. Nishimoto T, Satoh T, Takeuchi Tet al (2012) Critical role of CD4(+) CD25(+) regulatory T cells in preventing murine autoantibody-mediated thrombocytopenia. Exp Hematol 40:279-289
24. Aboul-Fotoh Lel M, Abdel Raheem MM, El-Deen MA et al (2011) Role of CD4+ CD25+ T cells in children with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 33:81-85
25. Johnsen J (2012) Pathogenesis in immune thrombocytopenia: new insights. Hematology Am Soc Hematol Educ Program 2012:306-312
26. Sakakura M, Wada H, Tawara I et al (2007) Reduced Cd4+ Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res 120:187-193 (Pubitemid 46754414)
27. Semple JW (2002) Immune pathophysiology of autoimmune thrombocytopenic purpura. Blood Rev 16:9-12
28. Cines DB, Bussel JB, Liebman HA et al (2009) The ITP syndrome: pathogenic and clinical diversity. Blood 113:6511-6521
29. Blatt SP, Lucey CR, Butzin CA et al (1993) Total lymphocyte count as a predictor of absolute CD4+ count and CD4+ percentage in HIV-infected persons. JAMA 269:622-626 (Pubitemid 23033526)
30. Shapiro NI, Karras DJ, Leech SH et al (1998) Absolute lymphocyte count as a predictor of CD4 count. Ann Emerg Med 32:323-328 (Pubitemid 28413481)
31. Napoli AM, Fischer CM, Pines JM et al (2011) Absolute lymphocyte count in the emergency department predicts a low CD4 count in admitted HIV-positive patients. Acad Emerg Med 18:385-389
32. Napoli AM, Maughan B, Murray R et al (2013) Use of the relationship between absolute lymphocyte count and CD4 count to improve earlier consideration of pneumocystis pneumonia in HIV-positive emergency department patients with pneumonia. J Emerg Med 44: 28-35
33. Meibohm B, Derendorf H, Mollmann H et al (1999) Mechanism-based PK/PD model for the lymphocytopenia induced by endogenous and exogenous corticosteroids. Int J Clin Pharmacol Ther 37: 367-376 (Pubitemid 29391068)
34. Zweiman B, Atkins PC, Bedard PM et al (1984) Corticosteroid effects on circulating lymphocyte subset levels in normal humans. J Clin Immunol 4:151-155 (Pubitemid 14146853)
35. Ginsburg C, Guillevin L, Sauvaget F et al (1993) Systemic diseases treated by corticoids, plasma exchange and cyclophosphamide: infectious complications and lymphopenia. Ann Med Interne (Paris) 144:15-19 (Pubitemid 23173608)
36. Craddock CG (1978) Corticosteroid-induced lymphopenia, immunosuppression, and body defense. Ann Intern Med 88:564-566
37. Pamuk GE, Pamuk ON, Baslar Z et al (2002) Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy. Ann Hematol 81:436-440 (Pubitemid 36067657)
38. Boren E, Gershwin ME (2004) Inflamm-aging: autoimmunity, and the immune-risk phenotype. Autoimmun Rev 3:401-406 (Pubitemid 38993363)
39. Prelog M (2006) Aging of the immune system: a risk factor for autoimmunity? Autoimmun Rev 5:136-139
40. Hasler P, Zouali M (2005) Immune receptor signaling, aging, and autoimmunity. Cell Immunol 233:102-108 (Pubitemid 41074062)
41. Cohen YC, Djulbegovic B, Shamai-Lubovitz O et al (2000) The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 160:1630-1638 (Pubitemid 30367902)